In vitro antibacterial activity and beta-lactamase stability of a new carbapenem, BO-2727.
The in vitro activity of BO-2727, a new carbapenem, was compared with those of meropenem, biapenem, imipenem, and ceftazidime. BO-2727 was four- or eightfold more active than the other carbapenems against methicillin-resistant staphylococci and Pseudomonas aeruginosa strains, including imipenem- and ceftazidime-resistant bacteria. BO-2727 was quite stable to penicillinases, cephalosporinases, and oxyiminocephalosporinases, but not to metallo-beta-lactamase. Time-kill studies against Staphylococcus aureus Smith, Escherichia coli ML4707, and P. aeruginosa GN11189 showed that BO-2727 has potent bactericidal activity at concentrations greater than the MIC.
Inoue
K
K
Episome Institute, Gunma-ken, Japan.
Hamana
Y
Y
Mitsuhashi
S
S
D001419:Bacteria / Q000187:drug effects*; D015780:Carbapenems / Q000378:metabolism / Q000494:pharmacology*; D004355:Drug Stability; D008826:Microbial Sensitivity Tests; D001618:beta-Lactamases / Q000494:pharmacology*
D015780:Carbapenems; C085890:BO 2727; D001618:beta-Lactamases